News
ME
2.190
-3.95%
-0.090
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
NASDAQ · 1d ago
WSJ. Magazine Celebrates Style & Tech in Silicon Valley
The Wall Street Journal · 6d ago
BRIEF-23Andme Announces Presentation Of Phase 1 Clinical Data For 23Me-00610, An Investigational Antibody Targeting Cd200r1, At The American Association For Cancer Research (Aacr) Annual Meeting 2023
Reuters · 03/14 22:52
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
NASDAQ · 03/02 12:30
23andMe Looking Promising For The Long Term
Seeking Alpha · 03/01 06:10
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
NASDAQ · 02/28 15:23
Berenberg Bank Sticks to Its Buy Rating for 23andMe Holding (ME)
TipRanks · 02/28 15:15
BRIEF-23Andme Announces First Patient Dosed For The Phase 2A Portion Of Its Phase 1/2A Study Of 23Me-00610
Reuters · 02/28 14:33
23andMe Doses First Patient in Trial of Investigational Drug for Advanced Cancer Treatment
23andMe Doses First Patient in Trial of Investigational Drug for Advanced Cancer Treatment
MT Newswires · 02/28 12:55
23andMe: Still On The Sidelines
Seeking Alpha · 02/28 07:15
Ambrx, Meihua top healthcare gainers; Aileron, CVRx lead losers' pack
Seeking Alpha · 02/21 15:01
23andMe Holding's Return On Capital Employed Insights
Benzinga · 02/10 14:49
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 02/09 17:50
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
Benzinga · 02/09 16:18
23andMe Fiscal Q3 Loss Narrows, Revenue Increases; Raises Fiscal 2023 Guidance; Shares Higher
23andMe Fiscal Q3 Loss Narrows, Revenue Increases; Raises Fiscal 2023 Guidance; Shares Higher
MT Newswires · 02/09 14:29
BRIEF-23Andme Reports Fy2023 Third Quarter Financial Results
Reuters · 02/08 22:10
23andMe Stock Jumps More Than 12% On Raised 2023 Guidance -- MarketWatch
MarketWatch · 02/08 21:51
23andMe stock jumps more than 12% on raised 2023 guidance
MarketWatch · 02/08 21:50
23andMe up 12% on 2023 outlook raise, quarterly beats
Seeking Alpha · 02/08 21:48
More
Webull provides a variety of real-time ME stock news. You can receive the latest news about 23Andme Holding Co through multiple platforms. This information may help you make smarter investment decisions.
About ME
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company's segments include Consumer & Research Services and Therapeutics. The Consumer & Research Services segment comprises its Personal Genome Service (PGS), telehealth business, and research services. Its PGS service provides customers with a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. Its telehealth platform provides patients with access to medical consultation and treatment. Through its research services, it uses its database of genetic and phenotypic information to identify targets for drug development. The Therapeutics segment focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies to improve patients lives.